U.S. Markets open in 8 hrs 11 mins

Wired News – Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson’s Disease Dementia

Stock Monitor: Aeterna Zentaris Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Anavex Life Sciences Corp. (NASDAQ: AVXL) ("Anavex"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AVXL as the Company's latest news hit the wire. On April 17, 2018, the Company, which is a publicly-traded biopharmaceutical organization dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, announced its plans of initiating the Phase-2 clinical trial for its lead candidate ANAVEX®2-73 in Parkinson's Disease Dementia (PDD). Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Aeterna Zentaris Inc. (NASDAQ: AEZS), which also belongs to the Healthcare sector as the Company Anavex Life Sciences. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=AEZS

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Anavex Life Sciences most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AVXL

PDD, A Debilitating Condition

Parkinson's Disease is a common neurological disorder observed in older adults. On average, this disease affects 2% of people aged 65 years and above. According to the Parkinson's Foundation, Parkinson's Disease affects approximately 1 million Americans. About 50% to 80% of people living with Parkinson's Disease eventually experience PDD. Parkinson's Disease causes brain changes in a certain region that plays an important role in movement. As the disease spreads, it begins to hamper mental functions such as memory, and the ability to pay attention and make sound judgments. However, currently there are no adequate treatment options for this condition.

About ANAVEX®2-73

Anavex's lead drug candidate, ANAVEX®2-73, is an oral available drug that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Anavex's pre-clinical studies validate its potential to reverse the course of Alzheimer's Disease. The drug also demonstrated anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, which highlight its potential to treat additional central nervous system (CNS) disorders, such as epilepsy.

On August 12, 2015, the Michael J. Fox Foundation for Parkinson's Research awarded Anavex a research grant to develop ANAVEX®2-73 for the treatment of Parkinson's Disease. The grant fully funded the pre-clinical study for moving ANAVEX®2-73 into a Parkinson's Disease clinical trial.

Phase-2 Trial with ANAVEX®2-73 in PDD

There is a significant unmet medical need for the treatment of people suffering with PDD. Thus, Anavex intends to commence the double-blind, randomized, placebo-controlled Phase-2 trial to evaluate the efficacy of ANAVEX®2-73 on the cognitive and motor impairment of PDD. The study has been submitted for approval to regulatory authorities in Europe. Post the approval, Anavex plans to initiate this clinical trial in the second half of 2018.

Christopher U Missling, PhD, President and Chief Executive Officer (CEO) at Anavex, expressed his excitement on commencing the Phase-2 Trial of ANAVEX®2-73 for patients suffering with PDD. He affirmed that the Company would remain focused on the discovery and development of potential treatments for neurological diseases with unmet needs, such as Alzheimer's Disease and Rett Syndrome.

Phase-2 Study of ANAVEX®2-73 for Rett Syndrome

Additionally, Anavex submitted an updated investigational new drug (IND) application to the US Food and Drug Administration (FDA) for the double blind, randomized, placebo-controlled ANAVEX®2-73 Phase-2 Study in Rett Syndrome during the first quarter of 2018. At present, the Company is working with the agency on this submission and expects initiation of the clinical trial in the second half of 2018.

Stock Performance Snapshot

April 18, 2018 - At Wednesday's closing bell, Anavex Life Sciences' stock rose 3.83%, ending the trading session at $2.17.

Volume traded for the day: 266.75 thousand shares.

After yesterday's close, Anavex Life Sciences' market cap was at $99.02 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was flat at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors